Advanced Solid Tumor Clinical Trials in Irving, Texas

7 studies are recruiting for advanced solid tumor in Irving, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

   This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), and in combination with standard …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Next Oncology Dallas, Irving, Texas

   Locations

   101 in total

   Run by

   BeOne Medicines

   See if you can join NCT06589596 on ClinicalTrials.gov

2. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

   This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Next Oncology Dallas, Irving, Texas

   Locations

   62 in total

   Run by

   BeOne Medicines

   See if you can join NCT06120283 on ClinicalTrials.gov

3. A Study of DS5361b in Participants With Advanced Solid Tumors

   This study aims to assess the safety, tolerability, and preliminary efficacy and to determine the MTD of DS5361b in monotherapy and combination with pembrolizumab in participants with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Irving, Texas

   Locations

   7 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT07182591 on ClinicalTrials.gov

4. Study of APR-1051 in Patients With Advanced Solid Tumors

   The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology -Dallas, Irving, Texas

   Locations

   5 in total

   Run by

   Aprea Therapeutics

   See if you can join NCT06260514 on ClinicalTrials.gov

5. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

   This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway altera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology Dallas, Irving, Texas

   Locations

   15 in total

   Run by

   Nuvectis Pharma, Inc.

   See if you can join NCT05873686 on ClinicalTrials.gov

6. A Study of YL201 in Patients With Advanced Solid Tumors

   This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohor…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   015, Irving, Texas

   Locations

   45 in total

   Run by

   MediLink Therapeutics (Suzhou) Co., Ltd.

   See if you can join NCT05434234 on ClinicalTrials.gov

7. A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

   This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subje…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Dallas, Irving, Texas

   Locations

   4 in total

   Run by

   OncoResponse, Inc.

   See if you can join NCT06090266 on ClinicalTrials.gov